Pre-Activity Questions

Currently, how confident are you in your: *

Please use the scale: 1=NOT at all confident, 2=Not very confident, 3=Somewhat confident, 4=Confident, 5=Very confident,

	1	2	3	4	5
Ability to discuss the appropriate symptomology and progressive characteristics of different multiple sclerosis subtypes?	Ability to discuss the appropriate symptomology and progressive characteristics of different multiple sclerosis subtypes? - 1	Ability to discuss the appropriate symptomology and progressive characteristics of different multiple sclerosis subtypes? - 2	Ability to discuss the appropriate symptomology and progressive characteristics of different multiple sclerosis subtypes? - 3	Ability to discuss the appropriate symptomology and progressive characteristics of different multiple sclerosis subtypes? - 4	Ability to discuss the appropriate symptomology and progressive characteristics of different multiple sclerosis subtypes? - 5
Understanding of the mechanisms of action of emerging therapies to treat multiple sclerosis?	Understanding of the mechanisms of action of emerging therapies to treat multiple sclerosis? - 1	Understanding of the mechanisms of action of emerging therapies to treat multiple sclerosis? - 2	Understanding of the mechanisms of action of emerging therapies to treat multiple sclerosis? - 3	Understanding of the mechanisms of action of emerging therapies to treat multiple sclerosis? - 4	Understanding of the mechanisms of action of emerging therapies to treat multiple sclerosis? - 5

According to the McDonald Diagnostic Criteria for MS, a patient with one clinical attack and objective clinical evidence ≥ 1 lesion in 2 of 4 critical areas, dissemination in time is required to make a diagnosis of MS. Which of the following is evidence of dissemination in time? *

A new T2 and/or gadolinium-enhancing lesions(s) on follow-up MRI, with reference to a baseline scan, follow-up MRI must be within 6 months of baseline MRI

A new T2 and/or gadolinium-enhancing lesions(s) on follow-up MRI, with reference to a baseline scan, follow-up MRI must be at least 6 months after baseline MRI

Simultaneous presence of asymptomatic gadolinium-enhancing and non-enhancing lesions at any time

Presence of asymptomatic gadolinium-enhancing without presence of non-enhancing lesions at any time

True or false: If a patient has 2 or more clinical attacks and objective clinical evidence of ≥ 2 lesions or objective clinical evidence of 1 lesion with reasonable historical evidence of a prior attack, no further evidence is required to make a diagnosis of MS. *

True

False

A patient has an MRI for sports-related head injury, and the MRI shows possible MS lesions. This patient has never had a clinical event that was suggestive of MS. What would this patient be classified as? *

The MS clinical subtype of progressing-relapsing MS has recently been removed; these patients are now included in which of the following 2013 phenotype and disease activity descriptions? *

Primary-progressive MS with activity

Secondary-progressive active MS

Primary-progressive not active and without disease progression

Secondary-progressive not active and without disease progression

Which of the following MS monoclonal antibodies is a humanized anti-CD20 and has been studied in the OPERA trial series and showed positive outcomes for relapsing remitting multiple sclerosis? *

Daclizumab

Vatelizumab

Ofatumamab

Ocrelizumab

The DECIDE trial was a 2-year, phase III active comparator trial with relapsing MS patients. Patients were randomized to receive a high-yield process of daclizumab (DAC HYP) or interferon beta-1a 30 mg IM weekly. What was the correct dosing of DAC HYP that resulted in better suppression of MRI lesions than the IFN β-1a? *

150 mg SC every 4 weeks

150 mg IM every 4 weeks

100 mg SC every 4 weeks

150 mg IM weekly

Which of the following is a potential role for biomarkers in MS? *

Early diagnosis

Pathological phenotype

Prediction of treatment response

All of the above

You have a patient currently on a rituximab treatment. Which of the following biomarkers can, to some extent, help in determining response to rituximab and whether the patient will need to be redosed or not? *

CSF Oligoclonal IgG bands

JCV Assay

CD19 expression on B-cells

Varicella Ab

Please take a moment to reflect on your current use of the practice strategies discussed in this activity. You will not be graded on your responses. Indicate how often you CURRENTLY use each of the following clinical practice strategies for your patients with multiple sclerosis. *

Please use the scale: 1=Never, 2=Not often, 3=Sometimes, 4=Often, 5=Always, N/A=Not applicable to me

	1	2	3	4	5	N/A
Inform patients of MS subtypes, including their symptoms and disease characteristics, in order to provide MS patients with information on managing their disease	Inform patients of MS subtypes, including their symptoms and disease characteristics, in order to provide MS patients with information on managing their disease - 1	Inform patients of MS subtypes, including their symptoms and disease characteristics, in order to provide MS patients with information on managing their disease - 2	Inform patients of MS subtypes, including their symptoms and disease characteristics, in order to provide MS patients with information on managing their disease - 3	Inform patients of MS subtypes, including their symptoms and disease characteristics, in order to provide MS patients with information on managing their disease - 4	Inform patients of MS subtypes, including their symptoms and disease characteristics, in order to provide MS patients with information on managing their disease - 5	Inform patients of MS subtypes, including their symptoms and disease characteristics, in order to provide MS patients with information on managing their disease - N/A
Utilize new and emerging therapies and stay current on the mechanism of action in specific treatment options	Utilize new and emerging therapies and stay current on the mechanism of action in specific treatment options - 1	Utilize new and emerging therapies and stay current on the mechanism of action in specific treatment options - 2	Utilize new and emerging therapies and stay current on the mechanism of action in specific treatment options - 3	Utilize new and emerging therapies and stay current on the mechanism of action in specific treatment options - 4	Utilize new and emerging therapies and stay current on the mechanism of action in specific treatment options - 5	Utilize new and emerging therapies and stay current on the mechanism of action in specific treatment options - N/A
Address patient-specific disease activity and develop individualized treatment plans for your MS patients	Address patient-specific disease activity and develop individualized treatment plans for your MS patients - 1	Address patient-specific disease activity and develop individualized treatment plans for your MS patients - 2	Address patient-specific disease activity and develop individualized treatment plans for your MS patients - 3	Address patient-specific disease activity and develop individualized treatment plans for your MS patients - 4	Address patient-specific disease activity and develop individualized treatment plans for your MS patients - 5	Address patient-specific disease activity and develop individualized treatment plans for your MS patients - N/A

Elsevier CME

Incorporating Personalized Patient Management Strategies into the Treatment of Multiple Sclerosis

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Credit

Certificate

Webform

Course navigation

You are here

Incorporating Personalized Patient Management Strategies into the Treatment of Multiple Sclerosis

Pre-Activity Questions

Pre-Activity Questions

Course Video

Post-Activity Test

Evaluation

Credit

Certificate

Webform

Course navigation